J&J, FDA Share Blame On Motrin "Phantom Recall"
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Sharfstein says agency "could've done better" in asking questions after it was contacted by J&J about problems with Motrin.
You may also be interested in...
FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.
FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.
J&J/McNeil Done With Post-Recall Personnel Changes – CEO Weldon
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.